Jazz Pharmaceuticals (JAZZ) Director Laura Hamill Receives RSU Award

What Happened Laura Hamill, a director of Jazz Pharmaceuticals plc, was granted 1,605 restricted stock units (RSUs) on August 5, 2026. The award was recorded as an acquisition (code A) at $0.00 per unit (grant value $0 on the Form 4). These RSUs represent a contingent right to receive one ordinary share per unit upon vesting.

Key Details

• Transaction date: 2026-08-05; Form 4 filed 2026-08-07 (appears timely under the two-business-day Form 4 rule).
• Grant: 1,605 RSUs; grant price reported $0.00; grant recorded under the issuer’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• Vesting: Units vest in full on July 23, 2027, subject to continuous service and certain conditions (see footnote).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Transaction code: A = Award/Grant.

Context RSUs are a form of compensation for directors and do not transfer shares until they vest; they are not an open-market purchase or sale. Because the units have a future vesting date and were granted as director compensation, this filing is generally routine and does not by itself signal an immediate change in insider sentiment or ownership.